DOCSLIB.ORG

COVID-19 Resources for Clinical Chemistry Laboratories

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Resources for Clinical Chemistry Laboratories COVID-19 Resources for Clinical Chemistry Laboratories Last updated: 8 September 2020 The following is a list of resources related to the laboratory management of the COVID-19 outbreak. Jump to section • Resources from governing bodies • Personal safety and use of PPE • Disease transmission • Diagnostic testing • Clinical features and the role of laboratory testing • Paediatrics • Maternal medicine • Treatment for COVID-19 • Research This collection of resources reflects a rapidly changing situation. We have not critically appraised all resources cited here for scientific validity but tried to present information that is believed to help laboratory professionals in formulating their local policies in a better- informed manner. The interim advice or conclusions presented here may change as more information is gathered. If you wish to add a resource or have any other feedback, please get in touch via the contact details below: Dr Simon Thompson Chemical Pathology Registrar, NSW Health Pathology [email protected] Contents Resources from governing bodies ................................................................................. 3 Australian Government advice ....................................................................................... 3 NSW Health ................................................................................................................... 3 World Health Organisation ............................................................................................. 3 RCPA ............................................................................................................................. 3 IFCC .............................................................................................................................. 3 The Centre for Evidence-Based Medicine (Oxford) ........................................................ 4 Medscape ...................................................................................................................... 4 FIND Diagnostics ........................................................................................................... 4 Joint Commission International ...................................................................................... 4 Resources from Singapore ............................................................................................ 4 Association for Quality Management in Laboratory Medicine ......................................... 4 US Food and Drug Administration .................................................................................. 4 Mayo Clinic .................................................................................................................... 4 Personal safety and use of PPE ..................................................................................... 4 Disease transmission ...................................................................................................... 6 Diagnostic testing for COVID-19 .................................................................................... 8 Guidelines and reviews .................................................................................................. 8 Genetic and molecular testing – validation and evaluation of methods ........................... 9 Genetic and molecular testing – other resources ........................................................... 9 Serology - validation and evaluation of methods .......................................................... 10 Serology – other resources .......................................................................................... 13 Others .......................................................................................................................... 14 Clinical features and the role of laboratory testing ..................................................... 15 Clinical characteristics of COVID-19 ............................................................................ 15 Inflammatory markers .................................................................................................. 19 Platelets and coagulation ............................................................................................. 19 Cardiovascular manifestations of COVID-19 ................................................................ 20 Renin-angiotensin-aldosterone system ........................................................................ 21 Miscellaneous .............................................................................................................. 22 COVID-19 in children ..................................................................................................... 24 Maternal Medicine ......................................................................................................... 25 Treatment of COVID-19 ................................................................................................. 26 COVID-19 research resources ...................................................................................... 28 Resources from governing bodies Australian Government advice Coronavirus Disease 2019 (COVID-19) CDNA National Guidelines for Public Health Units https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-novel- coronavirus.htm Coronavirus (COVID-19) resources for health professionals, including aged care providers, pathology providers and healthcare managers. https://www.health.gov.au/resources/collections/coronavirus-covid-19-resources-for-health- professionals-including-aged-care-providers-pathology-providers-and-healthcare-managers NSW Health COVID-19 resources for health professionals. https://www.health.nsw.gov.au/Infectious/diseases/Pages/coronavirus-professionals.aspx COVID-19 - clinical guidance and resources. https://www.health.nsw.gov.au/Infectious/covid- 19/Pages/Clinical-Guidance-and-resources.aspx Blood gas analysers during COVID-19: Cessation of pleural fluid testing and other guidance. https://www.health.nsw.gov.au/Infectious/covid-19/Pages/covid-blood-gas-analysers.aspx World Health Organisation Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19): interim guidance. https://apps.who.int/iris/handle/10665/331498 Infection prevention and control during health care when COVID-19 is suspected: interim guidance. https:// www.who.int/publications-detail/infection-prevention-and-control-during- health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125 Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical- guidance/laboratory-guidance Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19): interim guidance. https://apps.who.int/iris/handle/10665/331138 RCPA COVID-19 useful resources. https://www.rcpa.edu.au/Library/COVID-19-Updates/COVID- 19-Useful-Resources IFCC IFCC Information Guide on COVID-19. https://www.ifcc.org/ifcc-news/2020-03-26-ifcc- information-guide-on-covid-19/ RCPath (UK) Recommendations from RCPath and Professional Bodies (IBMS, ACP and ACB) Prioritisation/deferral of Pathology Laboratory Work (in light of SARSCoV-2 (COVID19) epidemic). https://www.rcpath.org/uploads/assets/f5123842-950f-49c5- bf69ed866a7ca3da/Prioritisation-deferral-of-pathology-laboratory-work.pdf The Centre for Evidence-Based Medicine (Oxford) Oxford COVID-19 Evidence Service. https://www.cebm.net/covid-19/ Medscape Medscape COVID-19 resources. https://www.medscape.com/resource/coronavirus FIND Diagnostics COVID-19 Diagnostics. https://www.finddx.org/covid-19/ Joint Commission International COVID-19 Resource page. https://www.jointcommissioninternational.org/news-and- support/coronavirus/ Resources from Singapore Practical laboratory considerations amidst the COVID-19 outbreak: early experience from Singapore: https://jcp.bmj.com/content/early/2020/03/20/jclinpath-2020-206563 Preparing the Biochemistry Laboratory for the Next Outbreak: Lessons from SARS in Singapore. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1240032/ COVID-19 in Singapore—Current Experience: Critical Global Issues That Require Attention and Action. https://jamanetwork.com/journals/jama/fullarticle/2761890 Association for Quality Management in Laboratory Medicine COVID-19 resources. https://www.aqmlm.org.uk/covid-19 US Food and Drug Administration Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency (revised). https://www.fda.gov/regulatory-information/search-fda-guidance- documents/policy-diagnostic-tests-coronavirus-disease-2019-during-public-health- emergency FDA list of in vitro diagnostics Emergency Use Authorisations. https://www.fda.gov/medical- devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd FDA - Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. https://www.fda.gov/regulatory-information/search-fda-guidance- documents/policy-diagnostic-tests-coronavirus-disease-2019-during-public-health- emergency Mayo Clinic COVID-19 Testing Resource Centre - https://news.mayocliniclabs.com/covid19/ Personal safety and use of PPE Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19): interim guidance. https://apps.who.int/iris/handle/10665/331498 Infection prevention and control during health care when COVID-19 is suspected: interim guidance. https:// www.who.int/publications-detail/infection-prevention-and-control-during-
Load more

Recommended publications
  • WEATHERING COVID-19: Lessons from Wuhan and Milan for Urban Governance and Sustainability
    Trinity College Trinity College Digital Repository Faculty Scholarship 7-2020 WEATHERING COVID-19: Lessons from Wuhan and Milan for Urban Governance and Sustainability Xiangming Chen Trinity College, [email protected] Yi Teresa Wu Follow this and additional works at: https://digitalrepository.trincoll.edu/facpub Part of the Asian Studies Commons, and the Urban Studies and Planning Commons Global Crisis ver the first few months of WEATHERING COVID-19: 2020, the novel coronavirus, O which erupted in the Chinese city of Wuhan around 1 January, Lessons from Wuhan and engulfed around 200 countries and regions, infected over 12 million people and killed over 550,000 as of 8 July. Milan for Urban Governance This rapid spread from one locality to the entire world has quickly mobilised and Sustainability our responses to fighting COVID-19. Little collective response, however, has BY XIANGMING CHEN AND YI TERESA WU taken place, leaving most nations to muster their own resources to stem the virus within their closed borders. This has facilitated comparing nation-based data on new cases, death counts and relative performances in containing the The global spread of COVID-19 great cities of the East and West – virus. However, it has overshadowed a has exposed the world’s largest and Wuhan and Milan – have responded local focus on responses to COVID-19, densest urban centres to bearing to the deadly virus, with their especially by the most affected cities. the brunt of this pandemic. The internal and external strengths and invisible virus has forced thriving constraints. We also take the reader The invisible virus has forced metropolises to empty their streets deep into the two cities’ neighbour- and shops to dead spaces absent of hoods for a realistic sense of how thriving metropolises to people and activity.
    [Show full text]
  • Journal of Blood Group Serology and Molecular Genetics Volume 34, Number 1, 2018 CONTENTS
    Journal of Blood Group Serology and Molecular Genetics VOLUME 34, N UMBER 1, 2018 This issue of Immunohematology is supported by a contribution from Grifols Diagnostics Solutions, Inc. Dedicated to advancement and education in molecular and serologic immunohematology Immunohematology Journal of Blood Group Serology and Molecular Genetics Volume 34, Number 1, 2018 CONTENTS S EROLOGIC M ETHOD R EVIEW 1 Warm autoadsorption using ZZAP F.M. Tsimba-Chitsva, A. Caballero, and B. Svatora R EVIEW 4 Proceedings from the International Society of Blood Transfusion Working Party on Immunohaematology Workshop on the Clinical Significance of Red Blood Cell Alloantibodies, Friday, September 2, 2016, Dubai A brief overview of clinical significance of blood group antibodies M.J. Gandhi, D.M. Strong, B.I. Whitaker, and E. Petrisli C A S E R EPORT 7 Management of pregnancy sensitized with anti-Inb with monocyte monolayer assay and maternal blood donation R. Shree, K.K. Ma, L.S. Er and M. Delaney R EVIEW 11 Proceedings from the International Society of Blood Transfusion Working Party on Immunohaematology Workshop on the Clinical Significance of Red Blood Cell Alloantibodies, Friday, September 2, 2016, Dubai A review of in vitro methods to predict the clinical significance of red blood cell alloantibodies S.J. Nance S EROLOGIC M ETHOD R EVIEW 16 Recovery of autologous sickle cells by hypotonic wash E. Wilson, K. Kezeor, and M. Crosby TO THE E DITOR 19 The devil is in the details: retention of recipient group A type 5 years after a successful allogeneic bone marrow transplant from a group O donor L.L.W.
    [Show full text]
  • China's Mental Health Support in Response to COVID-19
    Ju et al. Globalization and Health (2020) 16:102 https://doi.org/10.1186/s12992-020-00634-8 DEBATE Open Access China’s mental health support in response to COVID-19: progression, challenges and reflection Yumeng Ju1†, Yan Zhang1,2†, Xiaoping Wang1,2, Weihui Li1,2, Roger M. K. Ng3* and Lingjiang Li1* Abstract The continued spread of the coronavirus disease 2019 (COVID-19) has a serious impact on everyone across the globe, both physically and psychologically. In addition to proactive measures addressing physical survival needs and health protection, China has launched a mental health support system to cope with the widespread psychological stress during the pandemic and its aftermath. In this debate, the authors attempted to depict and reflect upon the overall framework of China’s mental health support, with particular reference to the psychological intervention in response to COVID-19 over the last few months. Although a lot of effort has been made to meet the mental health needs, the accessibility, acceptability and effectiveness of the support system still have much room for improvement. Therefore, it is very important to re-think the predicament and challenge on ways of enhancing public mental health emergency responses in China. The concepts of universality, timeliness and scientific rigour were proposed as a possible reform in preparation for large-scale natural or man-made disasters in the coming future. Keywords: China, COVID-19, Mental health, Psychological intervention, Preparedness Background quarantine and isolation), and a large number of fake Over the last few months, the continued spreading of news and media reports have increased emotional dis- coronavirus disease 2019 (COVID-19) has become a tress among the public [10].
    [Show full text]
  • Comparison of Histopathology, Immunofluorescence, and Serology
    Global Dermatology Cae Report ISSN: 2056-7863 Comparison of histopathology, immunofluorescence, and serology for the diagnosis of autoimmune bullous disorders: an update Seline Ali E1, Seline Lauren N1, Sokumbi Olayemi1* and Motaparthi Kiran2,3 1Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA 2Dermatopathology, Miraca Life Sciences, USA 3Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA Introduction In an ELISA, the target antigen of interest (such as the NC16a domain of BP180) is immobilized by physical adsorption or by The diagnosis of autoimmune bullous disorders (AIBDs) relies on antibody capture. When antibody capture is utilized, this is referred to several different diagnostic methods. These include histopathology, as “sandwich ELISA” because the target antigen is bound between the direct immunofluorescence (DIF), indirect immunofluorescence immobilizing antibody and the primary antibody. Primary antibodies (IIF), enzyme-linked immunosorbent assay (ELISA) and are present in the patient’s serum. Enzyme-linked secondary antibodies immunoblotting. When faced with a presumptive AIBD, the are then added which bind the Fc region of primary antibodies. most widely employed method for diagnosis by dermatologists is Substrate is added and converted by the enzyme into a signal. A a combination of histopathology and DIF. While DIF is still the resulting color change, fluorescence, or electrochemical signal is diagnostic method of choice for linear IgA bullous disease and IgA quantitatively measured and reported [5]. pemphigus, ELISA is a more accurate, cost-effective and less invasive method of diagnosis for several AIBDs including pemphigus vulgaris Western blot is synonymous with immunoblot. For this method, and foliaceus, based on currently available evidence [1-3].
    [Show full text]
  • Online-Only Appendix: List of Inclusion and Exclusion Criteria
    ONLINE-ONLY APPENDIX: LIST OF INCLUSION AND EXCLUSION CRITERIA INCLUSION CRITERIA [1] Male subjects between the ages of 35 and 70 years, inclusive, with Type 2 diabetes mellitus as defined by the American Diabetes Association (Diabetes care, Vol. 21: S5- S19, 1998) for more than one year. [2] Subjects must have Body Mass Index (BMI) < 36 kg/m². [3] Stable glycemic control (Hb A1C <11%). [4] Subjects must be off all oral hypoglycemic agents 24 hours prior to each study dosing day and off any investigational drug for at least four weeks. [5] Subjects must refrain from strenuous physical activity beginning 72 hours prior to admission and through the duration of the study. [6] Subjects must be willing and able to be confined to the Clinical Research Unit as required by the protocol. [7] Subjects must be willing and able to provide written informed consent. EXCLUSION CRITERIA [1] History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neurological or infectious disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication. [2] Subjects with gastroparesis, orthostatic hypotension and hypoglycemia unawareness (autonomic neuropathy). [3] Subjects with “brittle” diabetes or predisposition to severe hypoglycemia, e.g., 2 or more serious hypoglycemic episodes (requiring another’s assistance) within the past year, or any hospitalization or emergency room visit due to poor diabetic control within the past 6 months. [4] Evidence of significant active hematological disease and/or cumulative blood donation of 1 unit (500 mL) or more including blood drawn during clinical trials in the last 3 months.
    [Show full text]
  • Application of Quantitative Immunofluorescence to Clinical Serology: Antibody Levels of Treponema Pallidum GRACE L
    JOURNAL OF CLINICAL MICROBIOLOGY, May 1992, p. 1294-1296 Vol. 30, No. 5 0095-1137/92/051294-03$02.00/0 Copyright C 1992, American Society for Microbiology Application of Quantitative Immunofluorescence to Clinical Serology: Antibody Levels of Treponema pallidum GRACE L. PICCIOLO* AND DAVID S. KAPLAN Center for Devices and Radiological Health, Food and Drug Administration, 12200 Wilkins Avenue, Rockville, Maryland 20852 Received 27 March 1991/Accepted 20 January 1992 A previously reported method of quantitative immunofluorescence, employing a calibrated photometric system and chemically stabilized fluorescence intensity, was used to replace the subjective, visual method of endpoint determination with a quantitative, calibrated measurement of antibodies to Treponema paUlidum in serum. The results of the quantitative immunofluorescence method showed a 90% correlation with the subjective determinations of the visual method. A quantitative immunofluorescence (QIF) method to de- measured by using an acridine orange filter set, with a 400- to termine immunofluorescence with a quantitative, calibrated 440-nm excitation and LP 470 emission filters. photometric intensity of the fluorescent reaction product has Reducing agent. Dithioerythritol (DTE) (Sigma Chemical been reported previously by us (4). This method used uranyl Co., St. Louis, Mo.) was prepared as stock solution contain- glass slides in the calibration and standardization of the ing 0.3 M reducing agent in 0.5 M Tris buffer, pH 8.2 (Sigma microscope-photometer voltage measurements. To stabilize Chemical Co.). DTE was diluted 1:9 with standard buffered the fluorescence emission, dithioerythritol (DTE) was incor- glycerol mounting medium (Clinical Sciences, Inc., Whip- porated into the buffered glycerol mounting medium of the pany, N.J.) (4, 8).
    [Show full text]
  • Neurological Implications of Non-Critically Ill Patients with Coronavirus Disease 2019 in a Fangcang Shelter Hospital in Wuhan, China
    ORIGINAL RESEARCH published: 26 August 2020 doi: 10.3389/fneur.2020.00895 Neurological Implications of Non-critically Ill Patients With Coronavirus Disease 2019 in a Fangcang Shelter Hospital in Wuhan, China Nao Yan †, Zhipeng Xu †, Bin Mei, Yongzhe Gao, Dongwei Lv and Junjian Zhang* Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, China Edited by: Avindra Nath, Background: Coronavirus disease 2019 (COVID-19) is a new viral respiratory disease National Institute of Neurological Disorders and Stroke (NINDS), and has become a pandemic. Fever, weakness, and dry cough are the main clinical United States manifestations. However, little is known about neurological symptoms of non-critically ill Reviewed by: COVID-19 patients. Jiawei Wang, Beijing Tongren Hospital, Capital Objective: To investigate the neurological symptoms and implications of patients with Medical University, China non-critically ill COVID-19 patients. Tory P. Johnson, School of Medicine, Johns Hopkins Materials and Methods: This retrospective cohort study investigated all COVID-19 University, United States patients admitted to Wuhan East-West Lake Fangcang shelter hospital. Demographic *Correspondence: data, clinical manifestations, comorbidities, radiological data, the result of nucleic acid Junjian Zhang [email protected] test, and treatments were collected and analyzed. †These authors have contributed Results: Among 1,682 patients with confirmed non-critically ill COVID-19, 509 patients equally to this work and share (30.3%) had neurological symptoms, including myalgia (311, 18.5%), headache (216, first authorship 12.8%), fatigue (83, 4.9%), and dizziness (15, 0.9%). One hundred and fourteen patients Specialty section: (6.8%) were the expansion of pulmonary infection according to their chest CT images and This article was submitted to medical history.
    [Show full text]
  • Can Aerosols and Wastewater Be Considered As Potential Transmissional Sources of COVID-19 to Humans?
    European Journal of Environment and Public Health 2020, 4(2), em0047 e-ISSN: 2542-4904 https://www.ejeph.com Review Article Can Aerosols and Wastewater be Considered as Potential Transmissional Sources of COVID-19 to Humans? Soraia El Baz 1*, Boujamâa Imziln 1 1 Laboratory of Microbial Biotechnologies, Agrosciences and Environment (BioMAgE), Cadi Ayyad University, Faculty of Sciences Semlalia, P.O. Box 2390, Marrakech 40000, MOROCCO *Corresponding Author: [email protected] Citation: El Baz, S. and Imziln, B. (2020). Can Aerosols and Wastewater be Considered as Potential Transmissional Sources of COVID-19 to Humans?. European Journal of Environment and Public Health, 4(2), em0047. https://doi.org/10.29333/ejeph/8324 ARTICLE INFO ABSTRACT Received: 18 Apr. 2020 In view of the current situation regarding the COVID-19 disease, recently, published studies have proved the Accepted: 23 May 2020 higher aerosol and surface stability of COVID-19. This virus, can survive long time on wastewater and aerosol. Therefore, its transmission via contaminated waste surfaces and airborne transmission through aerosols can occur besides close-distance contacts. This article discusses the potential presence of the COVID-19 pandemic on aerosol, wastewater and sewage sludge. This article highlights the need for health protection, which should be considered to curb the rapid spread of COVID‐19. An eventual development of new specific techniques would be of great interest for controlling the environmental dissemination of these viruses in the current and eventual future outbreaks. Finally, levels of infectious virus in poor countries like Africa could be increase, due to lack of wastewater treatment. So, it is clear that to limit the transmission of COVID-19, a high disinfection methods and sustainable international collaborative work are required.
    [Show full text]
  • Clinical Placements Serology Screening for Students
    Gawler Place Medical Practice Level 1, Key Invest Building 49 Gawler Place Adelaide SA 5000 T: 08 8212 7175 F: 08 8212 1993 E: [email protected] www.adelaideunicare.com.au CLINICAL PLACEMENTS SEROLOGY SCREENING FOR STUDENTS Gawler Place Medical Practice have put together this Question and Answer sheet to assist you in meeting the requirements of SA Health’s Immunisation for Health Care Workers in South Australia Policy – August 2017. It is a requirement that all Health Care Workers have adequate immunisation against certain diseases prior to working in a clinical environment. What is Serology Screening and why do I need to do it? Serology Screening is a blood test that looks for antibodies in your blood. The purpose of such a test is to detect serum antibodies to prove protective immunity against a disease. Where can I have Serology Screening done? Gawler Place Medical Practice offer Serology Screening appointments to allow incoming students to have their serology screening completed, and where required, obtain their required vaccinations to meet SA Health’s Immunisation for Health Care Workers in South Australia – August 2017. Australian Clinical Labs are located within our Practice so that you can have your blood taken (if required) as soon as you have seen the doctor. How do I make an appointment? You may contact the practice to organise an appointment, our telephone number is 8212 7175 or make a booking online. Please make a long appointment booking. If you need to change or cancel an appointment please contact our Practice on (08) 2127175 as soon as possible so that your appointment can be offered to another person.
    [Show full text]
  • Macroeconomic Impact of COVID-19 in China and Policy Suggestions
    PricewaterhouseCoopers: Macroeconomic Impact of the COVID-19 in China and Policy Suggestions The outbreak of the COVID-19 not only threatens people’s lives and safety, but also has a significant impact on China’s economic development this year. Based on our close monitoring of the current situation, PwC analyzes the impact of the outbreak on economic growth and individual industries, and proposes countermeasures and macro policy recommendations. Part 1 I. The status and prospect Since the first case confirmed on December 8, 2019, the COVID-19 disease that broke out in Wuhan has continued to spread for 2 months. According to the official data reported on “Sina News”, as of 14:00 on February 10, 2020, the cumulative total of confirmed cases ran up to 40,235 nationwide, while suspect cases were 23,589, and 909 people died. Among them, Hubei Province, the worst-afflicted area, reported 29,631 confirmed cases (16,902 in Wuhan) and 871 deaths (681 in Wuhan). Among other provinces, Guangdong, Zhejiang and Henan each had more than 1,000 confirmed cases. There is no doubt that the severity of this new outbreak has exceeded the SARS 17 years ago, whether in terms of confirmed cases or deaths. Chart 1: Cumulative Nationwide Movements of the COVID-19 Number cases of Number cases of Source: Sina News It is worth noting that, since governments at all levels have significantly strengthened their prevention and control measures after the Spring Festival, cities with severe outbreaks, such as Wuhan, have in fact “sealed up”. In addition, most imported cases in other cities outside Hubei have passed the incubation period.
    [Show full text]
  • Iron Deficiency Anemia: Evaluation and Management MATTHEW W
    Iron Deficiency Anemia: Evaluation and Management MATTHEW W. SHORT, LTC, MC, USA, and JASON E. DOMAGALSKI, MAJ, MC, USA Madigan Healthcare System, Tacoma, Washington Iron deficiency is the most common nutritional disorder worldwide and accounts for approxi- mately one-half of anemia cases. The diagnosis of iron deficiency anemia is confirmed by the findings of low iron stores and a hemoglobin level two standard deviations below normal. Women should be screened during pregnancy, and children screened at one year of age. Supple- mental iron may be given initially, followed by further workup if the patient is not responsive to therapy. Men and postmenopausal women should not be screened, but should be evaluated with gastrointestinal endoscopy if diagnosed with iron deficiency anemia. The underlying cause should be treated, and oral iron therapy can be initiated to replenish iron stores. Paren- teral therapy may be used in patients who cannot tolerate or absorb oral preparations. (Am Fam Physician. 2013;87(2):98-104. Copyright © 2013 American Academy of Family Physicians.) ▲ Patient information: ron deficiency anemia is diminished red causes of microcytosis include chronic A handout on iron defi- blood cell production due to low iron inflammatory states, lead poisoning, thalas- ciency anemia, written by 1 the authors of this article, stores in the body. It is the most com- semia, and sideroblastic anemia. is available at http://www. mon nutritional disorder worldwide The following diagnostic approach is rec- aafp.org/afp/2013/0115/ I and accounts for approximately one-half of ommended in patients with anemia and is p98-s1.html. Access to anemia cases.1,2 Iron deficiency anemia can outlined in Figure 1.2,6-11 A serum ferritin level the handout is free and unrestricted.
    [Show full text]
  • My Epidemic Story a Guided Activity Workbook for Children, Families, Teachers and Caregivers
    MY EPIDEMIC STORY A GUIDED ACTIVITY WORKBOOK FOR CHILDREN, FAMILIES, TEACHERS AND CAREGIVERS A simple and straightforward guide that encourages mental health, creative expression, learning and coping. Use it to help children, teenagers and families overcome and go beyond bad memories and fears. Gilbert Kliman, M.D., Edward Oklan, M.D., Harriet Wolfe, M.D. The Children’s Psychological Health Center Culturally modified by China American Psychoanalytic Alliance: Elise Snyder, M.D., You Chen, M.D., Ping Hu, Maranda Sze, Ph.D., Xijie Yang, Ph.D. Copyright © May 20, 2008 The Children’s Psychological Health Center, Inc. 2105 Divisadero St., San Francisco, CA 94115 www.childrenspsychologicalhealthcenter.org Single copy use by downloading at no charge. A Guided Activity Workbook for Children’s Mental Health from The Children’s Psychological Health Center, Inc. 2105 Divisadero Street, San Francisco, CA 94115 (415)292-7119 www.childrenspsychologicalhealthcenter.org a nonprofit agency Mass reproduction, translation, modification and distribution rights available by license to governments, schools, mental health agencies and relief organizations. Single copy printing and copying without charge. First Edition as My Earthquake Story Some illustrations by Anne Kuniyuki Oklan, R.N.,are from a prior edition. © Copyright: 1989 Children’s Psychological Health Center, Inc. All rights reserved. My Epidemic Story edition © Copyright: February 16, 2020 Translation and further modification in collaboration with The China American Psychoanalytic Alliance 2 Preface Children, families, and whole societies are facing mental health challenges amidst epidemics such as the current novel Coronavirus has produced. Adult leadership is required to reduce maladaptive responses by children. This guided activity workbook is a small step in that preventive direction.
    [Show full text]